What is JSPR's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.02B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for JSPR?

P/E (TTM) is n/a and 52-week range is $0.32 to $2.69 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s JSPR figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for JSPR?

The company profile lists net income (TTM) near $-53M, EPS (TTM) near $-1.58 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Jasper Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Redwood City, California, US, 33.3M shares outstanding, ISIN US4718712023 when available from company profile and filing metadata.

Jasper Therapeutics Inc

$JSPR

Health Care · Biotechnology

IR Run Scenarios

$0.57

+1.82%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in enabling cures through hematopoietic stem cell therapy. The company is headquartered in Redwood City, California and currently employs 22 full-time employees. The company went IPO on 2019-11-20. The firm is focused on developing therapeutics targeting mast cell-driven diseases, such as Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CIndU), and Asthma. The firm's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (c-Kit) receptor on mast and stem cells. Briquilimab is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the cell-surface receptor c-Kit, also known as CD117, thereby inhibiting signaling through the receptor. The SCF/c-Kit pathway is a survival signal for mast cells. The company is also developing briquilimab as a one-time conditioning therapy for severe combined immunodeficiency (SCID) patients undergoing a second stem cell transplant for which it is conducting a Phase 1/2 clinical trial.

Employees

Website

jaspertx.com/

IPO

2019-11-20

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)